Skip to content
IARTIntegra Lifesciences Holdings Corp

Earnings

When Integra Lifesciences Holdings Corp reports, what it reported each quarter, and how the stock took the results.

70 quarters. Jun 30, 2009 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Feb 25, before the open

Thu, Feb 25, 2027in 100 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Feb 19 – Mar 1

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
$434.93M
Revenue, change from a year earlier: Q3 2026 +2.3%, Q2 2026 +0.8%, Q1 2026 +2.4%, Q4 2025 −1.7%
Net income
-$1.70M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$411.18M+2.3% vs Q3 2025

Latest results

  1. Q3 2026Oct 21, 2026, before the openThe release11.0%by the close of Oct 21
    Revenue
    $411.18M
    +2.3%
    Net income
    $14.85M
    N/M
    EPS
    $0.19
    N/M
    Total reported revenues of $411.2 million increased 2.3% on a reported basis and 2.5% on an organic basis compared to the prior year.
  2. Q2 2026Jul 29, 2026, before the openThe release16.5%by the close of Jul 29
    Revenue
    $418.76M
    +0.8%
    Net income
    $4.48M
    N/M
    EPS
    $0.06
    N/M
  3. Q1 2026May 5, 2026, before the openThe release+24.1%by the close of May 5
    Revenue
    $391.92M
    +2.4%
    Net income
    -$4.62M
    N/M
    EPS
    -$0.06
    N/M
  4. Q4 2025Feb 26, 2026, before the openThe release2.2%by the close of Feb 26
    Revenue
    $434.93M
    −1.7%
    Net income
    -$1.70M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Oct 21, 2026 · pre-marketOct 23, 202623 d10-Q$411.18M+2.3%$0.1911.0%
Q2 2026Jun 30, 2026Jul 29, 2026 · pre-marketJul 29, 202629 d10-Q$418.76M+0.8%$0.0616.5%
Q1 2026Mar 31, 2026May 5, 2026 · pre-marketMay 5, 202635 d10-Q$391.92M+2.4%-$0.06+24.1%
FY 2025
Q4 2025derivedDec 31, 2025Feb 26, 2026 · pre-marketFeb 26, 202657 d10-K$434.93M−1.7%—2.2%
Q3 2025Sep 30, 2025Oct 30, 2025 · pre-marketOct 30, 202530 d10-Q$402.06M+5.6%-$0.0723.5%
Q2 2025Jun 30, 2025Jul 31, 2025 · pre-marketJul 31, 202531 d10-Q$415.61M−0.6%-$6.31+6.1%
Q1 2025Mar 31, 2025May 5, 2025 · pre-marketMay 5, 202535 d10-Q$382.65M+3.7%-$0.3321.0%
FY 2024
Q4 2024derivedDec 31, 2024Feb 25, 2025 · pre-marketFeb 25, 202556 d10-K$442.65M+11.5%—+12.1%
Q3 2024Sep 30, 2024Nov 4, 2024 · pre-marketNov 4, 202435 d10-Q$380.83M−0.4%-$0.14+25.2%
Q2 2024Jun 30, 2024Jul 29, 2024 · pre-marketJul 29, 202429 d10-Q$418.18M+9.7%-$0.1620.3%
Q1 2024Mar 31, 2024May 6, 2024 · pre-marketMay 6, 202436 d10-Q$368.87M−3.1%-$0.04—
Earlier years, FY 2009 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QOct 23, 2026000077
10-QJul 29, 2026000058
10-QMay 5, 2026000041
10-KFeb 26, 2026000011
10-QOct 30, 2025000096
10-QJul 31, 2025000074
10-QMay 5, 2025000041
10-KFeb 25, 2025000017
10-QNov 4, 2024000108
10-QJul 29, 2024000094

Provenance

ProvenanceData status and checks

Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR